Diabeloop SA has just closed a series C funding round, securing $73 million to ramp global expansion for its DBL1 integrated smart system for patients with type 1 diabetes. “This will allow us to boost commercial roll-out and continue pursuing our growth strategy into Europe, the U.S. and Asia,” Erik Huneker, CEO of Diabeloop, told BioWorld.
Quoted European tech investor Gimv is setting up an independent life sciences arm and said it will increase both the size of its investments and the number of companies it backs.
Med-tech firms raising money in public or private financings, including: Adient Medical, Brain Scientific, Forza, , Pulse Biosciences, Third Rock Ventures.
Jiangsu Hengrui Medicine Co. Ltd., its subsidiary Shengdi Investment Management Holding Co. Ltd., and Hengrui Group are to invest ¥2.01 billion (US$301 million) to jointly set up an equity investment company targeting pharmaceutical and health care companies.
RSS
